Related Experiment Video
Updated: Feb 8, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Peritoneal Metastases from Malignant Mesothelioma
Claire Yue Li1, H Richard Alexander2
1Department of Surgery, New York Presbyterian Hospital, 170 William Street, New York, NY 10038, USA.
Diffuse malignant peritoneal mesothelioma (MPM) is a rare and fatal cancer. It progresses within the abdomen, often diagnosed late due to vague symptoms, and resists chemotherapy.
Area of Science:
- Oncology
- Cancer Research
Background:
- Diffuse malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer.
- MPM is characterized by locoregional progression within the abdominal cavity.
- The disease has a poor prognosis and is often diagnosed at an advanced stage.
Purpose of the Study:
- To summarize the key characteristics of diffuse malignant peritoneal mesothelioma.
- To highlight the diagnostic challenges and treatment resistance associated with MPM.
Main Methods:
- Review of existing literature on malignant peritoneal mesothelioma.
- Analysis of epidemiological and clinical data for MPM.
Main Results:
- MPM presents with nonspecific abdominal symptoms, delaying diagnosis.
- The cancer's locoregional growth pattern contributes to high morbidity and mortality.
- MPM demonstrates significant resistance to conventional chemotherapy.
Conclusions:
- MPM is a challenging malignancy with limited treatment options.
- Early diagnosis and novel therapeutic strategies are crucial for improving outcomes in MPM.
- Further research is needed to overcome chemotherapy resistance in MPM.
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis I: Introduction and Procedure
Peritoneal Dialysis III: Nursing Management
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

